Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma

References

• Al-SarrafMLeBlancMGiriPGChemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099J Clin Oncol1998164131013179552031
   PubMed Web of Science ®Google Scholar
• LeeAWLauWHTungSYPreliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study GroupJ Clin Oncol200523286966697516192584
   PubMed Web of Science ®Google Scholar
• LinJCJanJSHsuCYLiangWMJiangRSWangWYPhase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survivalJ Clin Oncol200321463163712586799
   PubMed Web of Science ®Google Scholar
• WeeJTanEHTaiBCRandomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic varietyJ Clin Oncol200523276730673816170180
   PubMed Web of Science ®Google Scholar
• LeeNXiaPQuiveyJMIntensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experienceInt J Radiat Oncol Biol Phys2002531122212007936
   PubMed Web of Science ®Google Scholar
• HerbstRSShinDMMonoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapyCancer20029451593161111920518
   PubMed Web of Science ®Google Scholar
• ChuaDTNichollsJMShamJSAuGKPrognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapyInt J Radiat Oncol Biol Phys2004591112015093894
   PubMed Web of Science ®Google Scholar
• MaBBPoonTCToKFPrognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma – a prospective studyHead Neck2003251086487212966511
   PubMed Web of Science ®Google Scholar
• LeongJLLohKSPuttiTCGohBCTanLKEpidermal growth factor receptor in undifferentiated carcinoma of the nasopharynxLaryngoscope2004114115315714710013
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalLancet Oncol2010111212819897418
   PubMed Web of Science ®Google Scholar
• MaBBKamMKLeungSFA phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinomaAnn Oncol20122351287129221948811
   PubMed Web of Science ®Google Scholar
• HeXXuJGuoWJiangXWangXZongDCetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary resultsFuture Oncol20139101459146724106897
   PubMed Web of Science ®Google Scholar
• FengHXGuoSPLiGRToxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinomaMed Oncol201431917025119503
   PubMed Web of Science ®Google Scholar
• CrombetTOsorioMCruzTUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol20042291646165415117987
   PubMed Web of Science ®Google Scholar
• RodriguezMORiveroTCDelCBRNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neckCancer Biol Ther20109534334920448462
   PubMed Web of Science ®Google Scholar
• ReddyBKLokeshVVidyasagarMSNimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patientsOral Oncol201450549850524613543
   PubMed Web of Science ®Google Scholar
• NowakPJWijersOBLagerwaardFJLevendagPCA three-dimensional CT-based target definition for elective irradiation of the neckInt J Radiat Oncol Biol Phys1999451333910477003
   PubMed Web of Science ®Google Scholar
• GregoireVLevendagPAngKKCT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelinesRadiother Oncol200369322723614644481
   PubMed Web of Science ®Google Scholar
• ThamIWHeeSWYeoRMTreatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy – The National Cancer Centre Singapore experienceInt J Radiat Oncol Biol Phys20097551481148619386431
   PubMed Web of Science ®Google Scholar
• WoldenSLChenWCPfisterDGKrausDHBerrySLZelefskyMJIntensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experienceInt J Radiat Oncol Biol Phys2006641576215936155
   PubMed Web of Science ®Google Scholar
• KamMKTeoPMChauRMTreatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experienceInt J Radiat Oncol Biol Phys20046051440145015590175
   PubMed Web of Science ®Google Scholar
• KwongDLShamJSLeungLHPreliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys200664237438116213105
   PubMed Web of Science ®Google Scholar
• NgWTLeeMCHungWMClinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys201179242042820452132
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med2006354656757816467544
   PubMed Web of Science ®Google Scholar
• NiuXHuCKongLExperience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinomaJ Cancer Res Clin Oncol201313961063107123525586
   PubMed Web of Science ®Google Scholar
• RamakrishnanMSEswaraiahACrombetTNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originmAbs200911414820046573
   PubMed Web of Science ®Google Scholar